Core decompression combined with platelet-rich plasma-augmented bone grafting for femur head necrosis: a systematic review and meta-analysis.
Journal
International journal of surgery (London, England)
ISSN: 1743-9159
Titre abrégé: Int J Surg
Pays: United States
ID NLM: 101228232
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
received:
19
10
2022
accepted:
11
12
2023
medline:
18
3
2024
pubmed:
5
1
2024
entrez:
5
1
2024
Statut:
epublish
Résumé
The clinical potential of biologic augmentation in core decompression and bone grafting for femoral head necrosis is widely acknowledged, with platelet-rich plasma (PRP) being a frequently employed biologic adjunct. However, its clinical application is not standardized, and high-level evidence is lacking. This study aimed to evaluate the efficacy and safety of core decompression and bone grafting combined with PRP for femur head necrosis. Several databases were systematically retrieved for randomized controlled trials comparing core decompression and bone grafting combined with or without PRP. A systematic review and meta-analysis were conducted following the PRISMA 2020 and AMSTAR 2 guidelines. The study is registered with PROSPERO under the code CRD42022361007, and it is also listed in the research registry under the identification number reviewregistry1537. Eleven studies with 642 participants (742 hips) were included. The pooled estimates revealed that when core decompression and bone grafting were combined with PRP, the Harris hip score (mean difference: 7.98; 95% CI: 5.77-10.20; P <0.001), visual analog scale (SMD: -0.68; 95% CI: -0.96 - -0.40; P <0.001) and the pain component of Harris hip score (SMD: 8.4; 95% CI: 4.12-12.68; P <0.001), and reduction of radiographic progression [risk ratio (RR): 0.40; 95% CI: 0.27-0.59; P <0.001] were superior to core decompression and bone grafting alone. Fewer patients with treatment failure (RR: 0.27; 95% CI: 0.14-0.52; P <0.001) and higher good-to-excellent results (RR: 1.48; 95% CI: 1.17-1.86; P <0.001) were observed in treatment groups than control groups. Meanwhile, the pooled analysis substantiated the superior safety profile of PRP (RR: 0.29; 95% CI: 0.11-0.77; P =0.01). The combination of core decompression and bone grafting with PRP is superior to the approach without PRP, demonstrating enhanced effectiveness in terms of function, pain relief, and radiographic progression. Additionally, it results in lower rates of treatment failure and adverse events. However, further high-quality RCTs are needed to evaluate their effectiveness due to methodological and implementation limitations observed in the existing evidence.
Sections du résumé
BACKGROUND
BACKGROUND
The clinical potential of biologic augmentation in core decompression and bone grafting for femoral head necrosis is widely acknowledged, with platelet-rich plasma (PRP) being a frequently employed biologic adjunct. However, its clinical application is not standardized, and high-level evidence is lacking. This study aimed to evaluate the efficacy and safety of core decompression and bone grafting combined with PRP for femur head necrosis.
METHODS
METHODS
Several databases were systematically retrieved for randomized controlled trials comparing core decompression and bone grafting combined with or without PRP. A systematic review and meta-analysis were conducted following the PRISMA 2020 and AMSTAR 2 guidelines. The study is registered with PROSPERO under the code CRD42022361007, and it is also listed in the research registry under the identification number reviewregistry1537.
RESULTS
RESULTS
Eleven studies with 642 participants (742 hips) were included. The pooled estimates revealed that when core decompression and bone grafting were combined with PRP, the Harris hip score (mean difference: 7.98; 95% CI: 5.77-10.20; P <0.001), visual analog scale (SMD: -0.68; 95% CI: -0.96 - -0.40; P <0.001) and the pain component of Harris hip score (SMD: 8.4; 95% CI: 4.12-12.68; P <0.001), and reduction of radiographic progression [risk ratio (RR): 0.40; 95% CI: 0.27-0.59; P <0.001] were superior to core decompression and bone grafting alone. Fewer patients with treatment failure (RR: 0.27; 95% CI: 0.14-0.52; P <0.001) and higher good-to-excellent results (RR: 1.48; 95% CI: 1.17-1.86; P <0.001) were observed in treatment groups than control groups. Meanwhile, the pooled analysis substantiated the superior safety profile of PRP (RR: 0.29; 95% CI: 0.11-0.77; P =0.01).
CONCLUSIONS
CONCLUSIONS
The combination of core decompression and bone grafting with PRP is superior to the approach without PRP, demonstrating enhanced effectiveness in terms of function, pain relief, and radiographic progression. Additionally, it results in lower rates of treatment failure and adverse events. However, further high-quality RCTs are needed to evaluate their effectiveness due to methodological and implementation limitations observed in the existing evidence.
Identifiants
pubmed: 38181110
doi: 10.1097/JS9.0000000000001028
pii: 01279778-990000000-00922
pmc: PMC10942211
doi:
Substances chimiques
Biological Products
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1687-1698Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Blood Transfus. 2013 Jan;11(1):102-7
pubmed: 22790266
BMJ. 2017 Sep 21;358:j4008
pubmed: 28935701
Int Orthop. 2008 Jun;32(3):283-7
pubmed: 17396260
Transfus Med Rev. 2015 Jan;29(1):52-61
pubmed: 25544600
Cell Metab. 2021 Feb 2;33(2):283-299.e9
pubmed: 33400911
Am J Sports Med. 2012 Aug;40(8):1742-9
pubmed: 22802273
J Cell Physiol. 2010 Nov;225(3):757-66
pubmed: 20568106
Stem Cell Res Ther. 2019 Sep 23;10(1):298
pubmed: 31547887
World J Orthop. 2015 Sep 18;6(8):590-601
pubmed: 26396935
Theranostics. 2017 Jan 15;7(3):733-750
pubmed: 28255363
Mater Sci Eng C Mater Biol Appl. 2017 Feb 1;71:372-380
pubmed: 27987720
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S200-7
pubmed: 22588745
J Orthop Surg Res. 2019 Dec 30;14(1):470
pubmed: 31888697
Clin Oral Implants Res. 2006 Apr;17(2):212-9
pubmed: 16584418
Stem Cell Res Ther. 2013 Jun 07;4(3):67
pubmed: 23759113
Connect Tissue Res. 2014 Aug;55(4):304-9
pubmed: 24874552
Clin Orthop Relat Res. 2012 Sep;470(9):2636-9
pubmed: 22760600
Expert Rev Anti Infect Ther. 2021 Jul;19(7):867-875
pubmed: 33259253
J Hip Preserv Surg. 2020 Nov 22;7(3):423-438
pubmed: 33948198
Cochrane Database Syst Rev. 2012 Mar 14;(3):CD008754
pubmed: 22419337
Arch Orthop Trauma Surg. 2013 Feb;133(2):153-65
pubmed: 23197184
J Arthroplasty. 2015 Sep;30(9 Suppl):11-5
pubmed: 26143238
J Periodontol. 2020 Feb;91(2):244-252
pubmed: 31376159
Biomed Res Int. 2016;2016:9060143
pubmed: 27403440
Platelets. 2020 Jul 3;31(5):661-666
pubmed: 31498027
Eur J Radiol. 2007 Jul;63(1):16-28
pubmed: 17555906
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
Platelets. 2021 Oct 3;32(7):950-959
pubmed: 32835568
Injury. 2014 Feb;45(2):369-73
pubmed: 24119830
J Bone Joint Surg Am. 2020 Jun 17;102(12):1084-1099
pubmed: 32282421
Am J Sports Med. 2019 Feb;47(2):347-354
pubmed: 30545242
Bone Joint J. 2017 Oct;99-B(10):1267-1279
pubmed: 28963146
J Arthroplasty. 2020 Feb;35(2):325-330
pubmed: 31587979
Int Orthop. 2019 Jun;43(6):1315-1320
pubmed: 30039197
Cytotherapy. 2013 Jul;15(7):830-9
pubmed: 23731763
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
Expert Opin Biol Ther. 2016;16(2):213-32
pubmed: 26561282
Br Med Bull. 2016 Jun;118(1):33-49
pubmed: 27298230
PLoS One. 2018 Jan 11;13(1):e0191093
pubmed: 29324848
J Clin Periodontol. 2021 Dec;48(12):1613-1623
pubmed: 34517437
Tissue Eng Part B Rev. 2019 Jun;25(3):225-236
pubmed: 30712506
Platelets. 2018 Mar;29(2):105-112
pubmed: 28649897
J Bone Joint Surg Am. 2008 Nov;90 Suppl 4:175-87
pubmed: 18984729
Cell Transplant. 2021 Jan-Dec;30:9636897211017833
pubmed: 34006140
Clin Orthop Relat Res. 2004 Dec;(429):131-8
pubmed: 15577477
J Orthop Surg Res. 2019 Sep 11;14(1):306
pubmed: 31511030
Biomed Res Int. 2020 Mar 07;2020:2642439
pubmed: 32219128
Chin Med J (Engl). 2015 Nov 5;128(21):2843-50
pubmed: 26521779
Int J Mol Sci. 2020 Jan 09;21(2):
pubmed: 31936605
Clin Orthop Relat Res. 2008 May;466(5):1093-103
pubmed: 18392909
Regen Ther. 2019 May 10;11:56-64
pubmed: 31193111
Am J Sports Med. 2023 Mar;51(4):1074-1086
pubmed: 35316112
BMJ. 2019 May 30;365:l2178
pubmed: 31147356
Int J Environ Res Public Health. 2022 Jun 15;19(12):
pubmed: 35742595
Zhongguo Gu Shang. 2020 Nov 25;33(11):1048-52
pubmed: 33269856
Arch Orthop Trauma Surg. 2016 Feb;136(2):165-74
pubmed: 26667621
J Bone Joint Surg Am. 2015 Oct 7;97(19):1604-27
pubmed: 26446969
Int J Surg. 2021 Apr;88:105906
pubmed: 33789826
Am J Sports Med. 2016 Mar;44(3):792-800
pubmed: 25925602
Regen Ther. 2022 Feb 15;19:144-153
pubmed: 35229012
J Clin Periodontol. 2017 Jan;44(1):67-82
pubmed: 27783851
Dtsch Arztebl Int. 2016 Jan 22;113(3):31-8
pubmed: 26857510
Biomed Pharmacother. 2021 Jul;139:111711
pubmed: 34243617